Stage III Cetuximab Trial Closed

It doesn’t help patients to add Erbitux to FOLFOX chemotherapy after surgery for stage III colon cancer a data monitoring committee for a clinical trial testing the new treatment has decided. Because the analysis showed that patients were not benefiting from adding Erbitux to FOLFOX chemotherapy, the trial has been closed according to a news release…  Read More

Colorectal Cancer News in Brief: October 2

Briefly: More colorectal cancer patients experience severe rash from Erbitux than other cancer patients, and significantly more men and younger people have severe rash than women and patients over 70. Where you live in the United States makes a big difference in your risk of being uninsured from more than 40 percent of people living in…  Read More

Early Tumor Shrinkage Points to Good Erbitux Outcomes

Patients with advanced colorectal cancer whose tumors have gotten smaller six weeks after starting treatment with Erbitux had a much longer time before their cancer got worse and almost twice the overall survival as patients whose tumors didn’t shrink. Patients in the BOND study had already gotten worse on standard chemotherapy and were receiving either Erbitux®…  Read More